<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223729</url>
  </required_header>
  <id_info>
    <org_study_id>8-12-00 A</org_study_id>
    <nct_id>NCT01223729</nct_id>
  </id_info>
  <brief_title>Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy</brief_title>
  <official_title>Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Catania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Minimal hepatic encephalopathy represents a common complication present in well-compensated
      cirrhotic patients that impairs patients daily functioning and health-related quality of
      life. Acetyl-L-carnitine has been shown to be useful in improving blood ammonia and cognitive
      functions in cirrhotic patients with minimal hepatic encephalopathy. This study evaluated the
      effects of acetyl-L-carnitine treatment on health related quality of life and on depression
      in patients with minimal hepatic encephalopathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date>November 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment>67</enrollment>
  <condition>Minimal Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Acetyl-L-Carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetyl-L-Carnitine</intervention_name>
    <description>2 g acetyl-L carnitine twice a day</description>
    <arm_group_label>Acetyl-L-Carnitine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo twice per day</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients diagnosed as having cirrhosis at the outpatient Internal Medicine of the
             Department of Senescence of Cannizzaro Hospital (Catania) were candidates for
             enrolment. The diagnosis of cirrhosis was based on clinical, biochemical and
             ultrasonographic or liver histological data.

        Exclusion Criteria:

          -  Exclusion criteria were overt hepatic encephalopathy or a history of overt HE; history
             of recent alcohol intake; infection; recent antibiotic use or gastrointestinal
             bleeding; history of recent use of drugs affecting psychometric performances like
             benzodiazepines, antiepileptics or psychotropic drugs; a history of shunt surgery or
             transjugular intrahepatic portosystemic shunt for portal hypertension; electrolyte
             imbalance; renal impairment; hepatocellular carcinoma; severe medical problems such as
             congestive heart failure, pulmonary disease or neurological or psychiatric disorder
             that could influence quality of life measurement; inability to perform
             neuropsycological tests.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>34 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Cannizzaro Hospital</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, Pennisi G, Rampello L. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci. 2008 Nov;53(11):3018-25. doi: 10.1007/s10620-008-0238-6. Epub 2008 Mar 21.</citation>
    <PMID>18357530</PMID>
  </reference>
  <verification_date>December 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mariano Malaguarnera</name_title>
    <organization>University of Catania</organization>
  </responsible_party>
  <keyword>Acetyl-L-carnitine;</keyword>
  <keyword>Minimal hepatic encephalopathy;</keyword>
  <keyword>Quality of life;</keyword>
  <keyword>Depression.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcarnitine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

